Universal screening of Lynch syndrome is ready for implementation

In conclusion, universal screening is good value for money and, together with near-universal screening (age-targeted screening for individuals <70 years), it should be proposed to decision-makers as a potential LS screening program. We agree with Grosse that context matters, and this is why each individual health system should select the most suitable model and adapt it for its own requirements. The challenges of LS screening will be to reach all CRC patients affected by LS, inform and test as many relatives as possible, offer effective surveillance interventions to reduce cancer morbidity and mortality among mutation carriers, and thus effectively maximize the health status of the population with the available resources.